Interim Data from KEYNOTE-555 Cohort B Demonstrate Benefit of Alternative Dosing Regimen

Interim data from cohort B of KEYNOTE-555, a phase I trial evaluating a 400 mg every 6-week dosing regimen of pembrolizumab in patients with metastatic melanoma, demonstrated a consistent benefit-risk profile.

Outcomes of Larotrectinib by Prior Therapy and Performance Status in TRK Fusion Cancer

Researchers analyzed pooled data from 159 patients enrolled in 3 larotrectinib trials to assess outcomes stratified by prior lines of therapy and ECOG performance status.

Prognostic Tool Accurately Predicts Cancer Survival Risk

A prognostic survival model, titled PROVIEW, was able to accurately predict changing cancer survival risk over time and may have the potential to be a useful prognostic tool that can be completed by patients.